Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 3,749 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,749 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $96.71, for a total transaction of $362,565.79. Following the sale, the chief financial officer now owns 8,492 shares in the company, valued at $821,261.32. The trade was a 30.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The shares were sold at an average price of $78.48, for a total transaction of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total transaction of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The shares were sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Stock Performance

GeneDx stock opened at $90.79 on Wednesday. The company’s 50-day moving average price is $84.57 and its 200-day moving average price is $70.78. GeneDx Holdings Corp. has a twelve month low of $7.72 and a twelve month high of $115.60. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a market cap of $2.55 billion, a PE ratio of -46.32 and a beta of 1.91.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $95.64 million for the quarter, compared to the consensus estimate of $82.24 million. On average, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Institutional Trading of GeneDx

Large investors have recently made changes to their positions in the business. MCF Advisors LLC increased its holdings in shares of GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after buying an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of GeneDx by 877.8% during the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock worth $27,000 after purchasing an additional 316 shares during the period. Global Retirement Partners LLC purchased a new position in shares of GeneDx during the 4th quarter worth about $28,000. Lazard Asset Management LLC purchased a new position in shares of GeneDx during the 4th quarter worth about $35,000. Finally, Comerica Bank purchased a new position in shares of GeneDx during the 4th quarter worth about $50,000. 61.72% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. TD Cowen lifted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and an average target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.